Publication: Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.
dc.contributor.author | Rodrigo, T | |
dc.contributor.author | Casals, M | |
dc.contributor.author | Caminero, J A | |
dc.contributor.author | García-García, J M | |
dc.contributor.author | Jiménez-Fuentes, M A | |
dc.contributor.author | Medina, J F | |
dc.contributor.author | Millet, J P | |
dc.contributor.author | Ruiz-Manzano, J | |
dc.contributor.author | Caylá, J | |
dc.contributor.author | Working Group of the Integrated Programme of Tuberculosis Research | |
dc.date.accessioned | 2023-01-25T08:35:02Z | |
dc.date.available | 2023-01-25T08:35:02Z | |
dc.date.issued | 2016-08-03 | |
dc.description.abstract | To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis (TB) treatment, and factors associated with fatality. TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We computed the CFR at the end of the intensive phase of TB treatment, and the incidence of death per 100 person-days (pd) of follow-up. We performed survival analysis using the Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confidence intervals (CI). A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths (48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The incidence of death was 0.028/100 pd. The following factors were associated with death during the intensive phase: being >50 years (HR = 36.9;CI:4.8-283.4); being retired (HR = 2.4;CI:1.1-5.1); having visited the emergency department (HR = 3.1;CI:1.2-7.7); HIV infection (HR = 3.4;CI:1.6-7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2-3.3) or non-standard treatments (HR = 2.68;CI:1.36-5.25); comprehension difficulties (HR = 2.8;CI:1.3-6.1); and smear-positive sputum (HR = 2.3-CI:1.0-4.8). There is a non-negligible CFR during the intensive phase of TB, whose reduction should be prioritised. The CFR could be a useful indicator for evaluating TB programs. | |
dc.identifier.doi | 10.1371/journal.pone.0159925 | |
dc.identifier.essn | 1932-6203 | |
dc.identifier.pmc | PMC4972388 | |
dc.identifier.pmid | 27487189 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972388/pdf | |
dc.identifier.unpaywallURL | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0159925&type=printable | |
dc.identifier.uri | http://hdl.handle.net/10668/10331 | |
dc.issue.number | 8 | |
dc.journal.title | PloS one | |
dc.journal.titleabbreviation | PLoS One | |
dc.language.iso | en | |
dc.organization | IBIS | |
dc.page.number | e0159925 | |
dc.pubmedtype | Journal Article | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antitubercular Agents | |
dc.subject.mesh | Coinfection | |
dc.subject.mesh | Female | |
dc.subject.mesh | HIV Infections | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Incidence | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Survival Analysis | |
dc.subject.mesh | Tuberculosis | |
dc.subject.mesh | Young Adult | |
dc.title | Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 11 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1